Xenon Pharmaceuticals
XENE
30 hedge funds and large institutions have $80.6M invested in Xenon Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 0 closing their positions.
151% more capital invested
Capital invested by funds: $32M → $80.6M (+$48.5M)
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more funds holding
Funds holding: 21 → 30 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$10.3M |
| 2 |
O
OrbiMed
New York
|
+$7.72M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$5.41M |
| 4 |
PA
Perceptive Advisors
New York
|
+$2.55M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$2.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$194K |
| 2 |
IPC
Invesco Private Capital
New York
|
-$185K |
| 3 |
LWIC
Leith Wheeler Investment Counsel
Vancouver,
British Columbia, Canada
|
-$13.9K |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$6.95K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$3.56K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $23K | +$14.6K | +1,894 | +207% |
|
|
27
Wells Fargo
San Francisco,
California
| $20K | -$3.56K | -461 | -16% |
|
28
JP Morgan Chase
New York
| $14K | +$12.3K | +1,589 | +1,432% |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $8K | +$857 | +111 | +13% |
|
30
Citigroup
New York
| $6K | – | – | – |
|
31
UBS Group
Zurich,
Switzerland
| $5K | +$4.77K | +617 | New |
|
XENE Hedge Fund Activity: Q3 2016 in Review
30 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2016, worth a combined $80.6M — up 151% from $32M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new XENE positions and 0 closed out — a net gain of 9 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was BVF Inc, adding an estimated $10.3M. The largest seller was Royal Bank of Canada, cutting an estimated $194K.
- 30 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2016, up from 21 in Q2 2016.
- Funds reported $80.6M of Xenon Pharmaceuticals stock for Q3 2016, up 151% quarter-over-quarter.
- 9 funds opened new Xenon Pharmaceuticals positions in Q3 2016 and 0 closed out, a net change of +9 holders.
- The largest Xenon Pharmaceuticals buyer in Q3 2016 was BVF Inc, an estimated $10.3M added.
- The largest Xenon Pharmaceuticals seller in Q3 2016 was Royal Bank of Canada, an estimated $194K sold.
Based on aggregated 13F filings for Q3 2016.